HIV 感染人群长期预后及影响因素探析:一项回顾性-前瞻性研究

注册号:

Registration number:

ChiCTR2200064212 

最近更新日期:

Date of Last Refreshed on:

2023-04-16 11:13:39 

注册时间:

Date of Registration:

2022-09-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

HIV 感染人群长期预后及影响因素探析:一项回顾性-前瞻性研究

Public title:

Long-term prognosis and influencing factors of HIV infection: a retrospective-prospective study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

HIV 感染人群长期预后及影响因素探析:一项回顾性-前瞻性研究

Scientific title:

Long-term prognosis and influencing factors of HIV infection: a retrospective-prospective study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

彭劼 

研究负责人:

彭劼 

Applicant:

Jie Peng 

Study leader:

Jie Peng 

申请注册联系人电话:

Applicant telephone:

+86 13802515784

研究负责人电话:

Study leader's
telephone:

+86 13802515784

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

pjie138@163.com

研究负责人电子邮件:

Study leader's E-mail:

pjie138@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市白云区广州大道北1838号

研究负责人通讯地址:

广东省广州市白云区广州大道北1838号

Applicant address:

1838 Guangzhou Avenue North, Baiyun District, Guangzhou, Guangdong

Study leader's address:

1838 Guangzhou Avenue North, Baiyun District, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学南方医院

Applicant's institution:

Nanfang Hospital, Southern Medical University

研究负责人所在单位:

南方医科大学南方医院

Affiliation of the Leader:

Nanfang Hospital, Southern Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

NFEC-2021-448

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南方医院医学伦理委员会

Name of the ethic committee:

NanFang Hospital Medical Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2021-12-31 00:00:00

伦理委员会联系人:

胡兴媛

Contact Name of the ethic committee:

Xingyuan Hu

伦理委员会联系地址:

中国广东省广州市广州大道北1838号

Contact Address of the ethic committee:

1838 Guangzhou Avenue North, Guangzhou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学南方医院

Primary sponsor:

Nanfang Hospital, Southern Medical University

研究实施负责(组长)单位地址:

广东省广州市白云区广州大道北1838号

Primary sponsor's address:

1838 Guangzhou Avenue North, Baiyun District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

南方医科大学南方医院

具体地址:

白云区广州大道北1838号

Institution
hospital:

Nanfang Hospital, Southern Medical University

Address:

1838 Guangzhou Avenue North, Baiyun Distric

经费或物资来源:

研究者自筹

Source(s) of funding:

The researchers were self-funded

研究疾病:

人类免疫缺陷病毒感染  

Target disease:

human immunodeficiency virus infection

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究的研究目的是观察 HIV 感染人群经过长期抗病毒治疗后的并发症发生率及死亡率;以及分析影响中国 HIV 感染人群并发症和死亡的危险因素。  

Objectives of Study:

The purpose of this study was to observe the incidence of complications and mortality in HIV-infected people after long-term antiviral therapy, and analysis the risk factor of Chinese HIV infected population influencing complications and deaths.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 患者依从性不佳;
2. 数据不完整;
3. 经研究者判断认为不适合参与本研究的HIV 患者;
4. 妊娠。

Exclusion criteria:

1. Poor patient compliance;
2. Incomplete data;
3. HIV patients deemed unsuitable for the study by the investigator;
4. pregnancy.

研究实施时间:

Study execute time:

From 2022-01-01 00:00:00 To 2031-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-09-30 00:00:00 To 2027-09-30 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

3000

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

南方医科大学南方医院 

单位级别:

三级甲等 

Institution
hospital:

Nanfang Hospital, Southern Medical University

Level of the institution:

Grade III Level A hospital

测量指标:

Outcomes:

指标中文名:

HIV定量

指标类型:

主要指标

Outcome:

HIV quantitative

Type:

Primary indicator

测量时间点:

测量方法:

PCR

Measure time point of outcome:

Measure method:

指标中文名:

CD4计数

指标类型:

主要指标

Outcome:

CD4 counts

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CD8计数

指标类型:

主要指标

Outcome:

CD8 counts

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

blood routine examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿常规

指标类型:

次要指标

Outcome:

urine routines

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪常规

指标类型:

次要指标

Outcome:

stool froutine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

次要指标

Outcome:

renal function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

次要指标

Outcome:

liver function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

乙肝两对半

指标类型:

次要指标

Outcome:

hepatitis B serological markers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

HBV 定量

指标类型:

次要指标

Outcome:

HBV quantitative

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

梅毒螺旋体颗粒凝集试验

指标类型:

附加指标

Outcome:

TPPA

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心肌酶谱

指标类型:

附加指标

Outcome:

myocardial enzyme

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

乳酸

指标类型:

附加指标

Outcome:

lactic acid

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

电解质

指标类型:

附加指标

Outcome:

electrolyte

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腹部超声

指标类型:

附加指标

Outcome:

abdomen ultrasound

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

瞬时肝脏弹性检测

指标类型:

附加指标

Outcome:

Transient liver elasticity measurement

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

骨密度

指标类型:

副作用指标

Outcome:

bone mineral density

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

问卷调查

指标类型:

附加指标

Outcome:

questionnaire survey

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身高

指标类型:

次要指标

Outcome:

height

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

次要指标

Outcome:

weight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

faeces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

淋巴结

组织:

淋巴结

Sample Name:

lymph gland

Tissue:

lymph gland

人体标本去向

使用后销毁  

说明

仅HIV相关淋巴瘤患者

Fate of sample:

Destruction after use  

Note:

Only for patients with HIV associated lymphoma

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

NA

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NA

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2022-09-30 22:04:34